The role of modified-release formulations in hypnotic therapy for insomnia

Terry Young, Sanjay R. Patel, David N. Neubauer, David L. Ginsberg, Eric Hollander

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

In addition to the psychological and medical health risks associated with lack of adequate sleep, effects of insomnia include impaired daytime functioning and decreased quality of life. Many patients experience delayed sleep onset, frequent awakenings, early waking, or nonrestorative sleep. Longitudinal data on insomnia indicate that the prevalence of persistent/chronic insomnia is high and appears to be characterized by multiple symptoms related to initiating or maintaining sleep. Physiologic studies indicate that short-term sleep restriction can cause physiologic problems that lead to long-term health consequences, such as high blood pressure, impaired glucose tolerance, and systemic inflammation. Epidemiologic studies have shown that sleep deprivation is independently associated with increased risk of cardiovascular disease, diabetes, obesity, and mortality. While the available agents are effective, those with a long half life may have carryover effects while short-acting agents may not provide enough sleep continuity. Pharmacologic therapies available for patients who suffer from insomnia include immediate-release nonbenzodiazepine hypnotics, which have a positive benefit/risk profile compared to the benzodiazepines. Modified-release (MR) formulations of these agents may offer the additional benefit of improving sleep continuity throughout the night without sacrificing the rapid elimination properties that minimize next-day residual effects. MR agents in development include zolpidem MR and indiplon MR.

Original languageEnglish (US)
JournalCNS Spectrums
Volume10
Issue number8
StatePublished - Aug 2005
Externally publishedYes

Fingerprint

Sleep Initiation and Maintenance Disorders
Sleep
Therapeutics
Sleep Deprivation
Glucose Intolerance
Health
Hypnotics and Sedatives
Benzodiazepines
Half-Life
Epidemiologic Studies
Cardiovascular Diseases
Obesity
Quality of Life
Psychology
Hypertension
Inflammation
Mortality

ASJC Scopus subject areas

  • Neuropsychology and Physiological Psychology

Cite this

Young, T., Patel, S. R., Neubauer, D. N., Ginsberg, D. L., & Hollander, E. (2005). The role of modified-release formulations in hypnotic therapy for insomnia. CNS Spectrums, 10(8).

The role of modified-release formulations in hypnotic therapy for insomnia. / Young, Terry; Patel, Sanjay R.; Neubauer, David N.; Ginsberg, David L.; Hollander, Eric.

In: CNS Spectrums, Vol. 10, No. 8, 08.2005.

Research output: Contribution to journalArticle

Young, T, Patel, SR, Neubauer, DN, Ginsberg, DL & Hollander, E 2005, 'The role of modified-release formulations in hypnotic therapy for insomnia', CNS Spectrums, vol. 10, no. 8.
Young, Terry ; Patel, Sanjay R. ; Neubauer, David N. ; Ginsberg, David L. ; Hollander, Eric. / The role of modified-release formulations in hypnotic therapy for insomnia. In: CNS Spectrums. 2005 ; Vol. 10, No. 8.
@article{a3b385120fec4ace8ec6dcf2b15cd4e0,
title = "The role of modified-release formulations in hypnotic therapy for insomnia",
abstract = "In addition to the psychological and medical health risks associated with lack of adequate sleep, effects of insomnia include impaired daytime functioning and decreased quality of life. Many patients experience delayed sleep onset, frequent awakenings, early waking, or nonrestorative sleep. Longitudinal data on insomnia indicate that the prevalence of persistent/chronic insomnia is high and appears to be characterized by multiple symptoms related to initiating or maintaining sleep. Physiologic studies indicate that short-term sleep restriction can cause physiologic problems that lead to long-term health consequences, such as high blood pressure, impaired glucose tolerance, and systemic inflammation. Epidemiologic studies have shown that sleep deprivation is independently associated with increased risk of cardiovascular disease, diabetes, obesity, and mortality. While the available agents are effective, those with a long half life may have carryover effects while short-acting agents may not provide enough sleep continuity. Pharmacologic therapies available for patients who suffer from insomnia include immediate-release nonbenzodiazepine hypnotics, which have a positive benefit/risk profile compared to the benzodiazepines. Modified-release (MR) formulations of these agents may offer the additional benefit of improving sleep continuity throughout the night without sacrificing the rapid elimination properties that minimize next-day residual effects. MR agents in development include zolpidem MR and indiplon MR.",
author = "Terry Young and Patel, {Sanjay R.} and Neubauer, {David N.} and Ginsberg, {David L.} and Eric Hollander",
year = "2005",
month = "8",
language = "English (US)",
volume = "10",
journal = "CNS Spectrums",
issn = "1092-8529",
publisher = "MBL Communications",
number = "8",

}

TY - JOUR

T1 - The role of modified-release formulations in hypnotic therapy for insomnia

AU - Young, Terry

AU - Patel, Sanjay R.

AU - Neubauer, David N.

AU - Ginsberg, David L.

AU - Hollander, Eric

PY - 2005/8

Y1 - 2005/8

N2 - In addition to the psychological and medical health risks associated with lack of adequate sleep, effects of insomnia include impaired daytime functioning and decreased quality of life. Many patients experience delayed sleep onset, frequent awakenings, early waking, or nonrestorative sleep. Longitudinal data on insomnia indicate that the prevalence of persistent/chronic insomnia is high and appears to be characterized by multiple symptoms related to initiating or maintaining sleep. Physiologic studies indicate that short-term sleep restriction can cause physiologic problems that lead to long-term health consequences, such as high blood pressure, impaired glucose tolerance, and systemic inflammation. Epidemiologic studies have shown that sleep deprivation is independently associated with increased risk of cardiovascular disease, diabetes, obesity, and mortality. While the available agents are effective, those with a long half life may have carryover effects while short-acting agents may not provide enough sleep continuity. Pharmacologic therapies available for patients who suffer from insomnia include immediate-release nonbenzodiazepine hypnotics, which have a positive benefit/risk profile compared to the benzodiazepines. Modified-release (MR) formulations of these agents may offer the additional benefit of improving sleep continuity throughout the night without sacrificing the rapid elimination properties that minimize next-day residual effects. MR agents in development include zolpidem MR and indiplon MR.

AB - In addition to the psychological and medical health risks associated with lack of adequate sleep, effects of insomnia include impaired daytime functioning and decreased quality of life. Many patients experience delayed sleep onset, frequent awakenings, early waking, or nonrestorative sleep. Longitudinal data on insomnia indicate that the prevalence of persistent/chronic insomnia is high and appears to be characterized by multiple symptoms related to initiating or maintaining sleep. Physiologic studies indicate that short-term sleep restriction can cause physiologic problems that lead to long-term health consequences, such as high blood pressure, impaired glucose tolerance, and systemic inflammation. Epidemiologic studies have shown that sleep deprivation is independently associated with increased risk of cardiovascular disease, diabetes, obesity, and mortality. While the available agents are effective, those with a long half life may have carryover effects while short-acting agents may not provide enough sleep continuity. Pharmacologic therapies available for patients who suffer from insomnia include immediate-release nonbenzodiazepine hypnotics, which have a positive benefit/risk profile compared to the benzodiazepines. Modified-release (MR) formulations of these agents may offer the additional benefit of improving sleep continuity throughout the night without sacrificing the rapid elimination properties that minimize next-day residual effects. MR agents in development include zolpidem MR and indiplon MR.

UR - http://www.scopus.com/inward/record.url?scp=24144458575&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24144458575&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:24144458575

VL - 10

JO - CNS Spectrums

JF - CNS Spectrums

SN - 1092-8529

IS - 8

ER -